- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01520558
CNDO-109-AANK for AML in First Complete Remission (CR1)
30 maj 2017 uppdaterad av: Coronado Biosciences, Inc.
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
This is a multi-center, open-label, non-controlled, non-randomized dose-escalating Phase 1 clinical study designed to examine the safety of infusing escalating doses of CNDO-109-Activated Allogeneic Natural Killer Cells-(from a first or second degree relative), after a preparatory chemotherapy regimen, in adult patients with acute myeloid leukemia (AML) who are in their first complete remission at the time of enrollment, are not candidates for stem cell transplant, and are considered to be at high risk for recurrence.
Studieöversikt
Status
Okänd
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
12
Fas
- Fas 2
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Florida
-
Tampa, Florida, Förenta staterna, 33612
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55455
- University of Minnesota - Masonic Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, Förenta staterna, 63110
- Washington University
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29425
- Medical University of South Carolina
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- The patient has pathologically documented AML and is in CR1 at the time of the screening visit
- The patient achieved CR1 within 10 weeks of the screening visit; the patient may have received post-remission consolidation therapy (except for transplant) prior to the screening visit
- A bone marrow aspiration performed within 21 days prior to the start of pre-infusion preparative therapy confirms the patient is in CR1
The patient has either refused or is not considered an appropriate immediate candidate for transplantation and is considered to be at high risk for recurrence by having at least one of the following prognostic factors:
- High risk cytogenetics (-5, -7, del(5q), abnormal 3q, 11q23 translocations, complex cytogenetics) or if cytogenetics are normal the presence of a FLT3 mutation without a NPM1 mutation
- Age > 60 years
- Antecedent hematological disorder (AHD)
- AML that is considered to be therapy-related
- FAB subtype M0 (minimally differentiated acute myeloblastic leukemia), M6 (acute erythroid leukemias, including erythroleukemia (M6a) and pure erythroid leukemia (M6b)), or M7 (acute megakaryoblastic leukemia)
- The patient is male or female, age 18 years or older
- The patient has an ECOG performance status of 0, 1, or 2
- The patient has an available NK cell donor who is a HLA haploidentical first-degree (parent, child, or sibling) or second-degree (child of a sibling) relative; minimum testing will be for HLA-A, HLA-B, and HLA-DR with donors matched for 3/6, 4/6 or 5/6 antigens
- The patient has an absence of coexisting medical problems that would significantly increase the risk of the chemotherapy procedure (e.g. poor left ventricular ejection fraction [LVEF<40%])
- The patient has recovered from reversible toxicity from prior therapy. Permanent and stable side effects or changes are acceptable if ≤ Grade 1 (CTCAE, v4.03)
- The patient has serum creatinine <2×ULN and not rising for at least 2-4 weeks before chemotherapy. If elevated, the 24-hour creatinine clearance must be >50 mL/min
- The patient has serum total bilirubin < 2 g/dL (unless the patient has a diagnosis of Gilbert's disease), SGOT (ALT) <3.5×ULN, and SGPT (AST) <3.5×ULN
- The patient has an absolute neutrophil count (ANC) ≥1000/µL, platelets ≥100,000/µL and is not transfusion dependent for platelets and/or red cells
- The patient has LVEF ≥40% by ECHO or MUGA scan and no clinically significant abnormalities in 12-lead ECG
- The patient has a PT (or INR) and PTT up to 1.25×ULN
- The patient must not be dependent on supplemental oxygen
- The patient is using an effective contraceptive (per the institutional standard), if procreative potential exists
- The patient must be willing and able to comply with all study protocol requirements. The patient or a legally authorized representative must fully understand all elements of the informed consent and have signed the informed consent according to institutional and federal regulatory requirements
- The patient has not received an investigational chemotherapy within the last 28 days prior to the screening visit and has never received investigational immunotherapy. In addition, the patient must not receive treatment for AML (including treatment with IL-2 or IFNγ) in the interval of time between the screening visit and initiation of pre-infusion preparative therapy
Exclusion Criteria:
- The patient had a previous bone marrow or stem cell transplant
- The patient is seropositive for HIV 1, HIV 2, HBV, or HCV
- The patient has a psychiatric, addictive, neurological or other disorder that compromises the ability to give informed consent or comply with study requirements
- The patient is pregnant (confirmed by urine or serum pregnancy test) or lactating
- The patient has a recently diagnosed active malignancy requiring therapy
- The patient has an uncontrolled infection, or is receiving anti-fungal treatment for an ongoing infection
- The patient has known hypersensitivity to bovine proteins
- The patient has any condition that will place the patient at undue risk or discomfort as a result of adherence to study procedures
- The patient requires treatment with corticosteroids at a dose > 0.1 mg/kg/day or has a known allergy to DSMO
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: CNDO-109-AANK Cells Dose 1
In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the lowest of these three doses (dose 1) is 3×10^5 cells/kg recipient body weight.
In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
|
Single dose, infusion
Andra namn:
|
Experimentell: CNDO-109-AANK Cells Dose 2
In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the middle dose of these three doses (dose 2) is 1×10^6 cells/kg recipient body weight.
In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
|
Single dose, infusion
Andra namn:
|
Experimentell: CNDO-109-AANK Cells Dose 3
In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the highest dose of these three doses (dose 3) is 3×10^6 cells/kg recipient body weight.
In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
|
Single dose, infusion
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Define MTD
Tidsram: up to 30 days post dose
|
The primary objective is to define the maximum tolerated dose (MTD), or the maximum tested dose where multiple dose-limiting toxicities (DLTs) are not observed, of CNDO-109-Activated Allogeneic Natural Killer Cells infused after preparative chemotherapy, administered to patients with acute myeloid leukemia (AML) who are in their first complete remission (CR1) at the time of enrollment and are considered to be at high risk for recurrence.
The MTD outcome measure is presented as number of participants with DLTs.
|
up to 30 days post dose
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Additional Safety Profile Beyond MTD
Tidsram: up to 360 days post dose
|
Characterize the safety profile of CNDO-109-Activated Allogeneic Natural Killer Cells infusion after preparative therapy by measurement of adverse events, safety labs, vital signs, bone marrow biopsy/aspiration and physical examination.
|
up to 360 days post dose
|
Efficacy
Tidsram: from the date of documented CR until the first documented progression date or until day 360 post dose whichever is sooner
|
Determine relapse free survival (RFS) and overall survival (OS) following infusion with CNDO-109-Activated Allogeneic Natural Killer Cells.
|
from the date of documented CR until the first documented progression date or until day 360 post dose whichever is sooner
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 december 2012
Primärt slutförande (Faktisk)
1 mars 2016
Avslutad studie (Förväntat)
1 februari 2018
Studieregistreringsdatum
Först inskickad
24 januari 2012
Först inskickad som uppfyllde QC-kriterierna
25 januari 2012
Första postat (Uppskatta)
30 januari 2012
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
29 juni 2017
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
30 maj 2017
Senast verifierad
1 april 2017
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CNDO109-001
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Akut myeloid leukemi
-
University of PennsylvaniaAktiv, inte rekryterandeAkut myeloid leukemi, i återfall | Akut myeloid leukemi, refraktär | Akut myeloid leukemi, pediatriskFörenta staterna
-
Betta Pharmaceuticals Co., Ltd.Har inte rekryterat ännuAkut Myeloid Leukemi LeukemiKina
-
Xuzhou Medical UniversityRekryteringAkut myeloid leukemi, i återfall | Akut myeloid leukemi refraktärKina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RekryteringNydiagnostiserad akut myeloid leukemi (AML)Kina
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RekryteringAkut myeloid leukemi, i återfall | Akut myeloid leukemi refraktärKina
-
Xuzhou Medical UniversityRekryteringAkut myeloid leukemi, i återfall | Akut myeloid leukemi refraktärKina
-
Bio-Path Holdings, Inc.RekryteringAkut myeloid leukemi, i återfall | Akut myeloid leukemi refraktärFörenta staterna
-
Washington University School of MedicineIndragenRefraktär Akut Myeloid Leukemi | Återfall av akut myeloid leukemiFörenta staterna
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.AvslutadAkut myeloid leukemi | Refraktär Akut Myeloid Leukemi | Återfall av akut myeloid leukemiFörenta staterna
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.RekryteringMyeloid malignitet | Återfall/refraktär Akut Myeloid LeukemiKina